New UK Biotech MiroBio Raises $34m For Autoimmune Disease Research
Executive Summary
Company is keeping its cards close to chest on exact mechanism as it enters increasingly competitive autoimmune disease field.
You may also be interested in...
Gilead Grabs MiroBio's Checkpoint Agonists For $405m
Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences.
Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.
Finance Watch: 3Q Biopharma Venture Capital Financings Fell From 2Q Spike
VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.